

Appl. No. 10/006,011  
Amendment

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (cancelled).
2. (cancelled).
3. (cancelled).
4. (cancelled).
5. (cancelled).
6. (cancelled).
7. (cancelled).
8. (cancelled).
9. (cancelled).
10. (cancelled).
11. (cancelled).
12. (cancelled).
13. (cancelled).

Appl. No. 10/006,011  
Amendment

14. (cancelled).

15. (currently amended) A pharmaceutical composition, comprising:

a) a polypeptide consisting of the amino acid sequence SEQ ID NO:3 endorepellin, wherein said endorepellin consists of amino acid residues 3687 to 4391 (SEQ ID NO:3) of perlecan (SEQ ID NO:2), or a an endorepellin fragment of said polypeptide which comprises the amino acid sequence SEQ ID NO:10 having and has angiogenesis-inhibiting activity, wherein said endorepellin fragment comprises amino acid residues 4182 to 4391 (SEQ ID NO:10) of perlecan; and

b) a pharmaceutically acceptable carrier or excipient.

16. (canceled)

17. (canceled)

18. (currently amended) The pharmaceutical composition of claim 15, wherein said endorepellin fragment consists of the amino acid sequence SEQ ID NO:9 residues 4108 to 4391 (SEQ ID NO:9) of perlecan.

19. (currently amended) The pharmaceutical composition of claim 15, wherein said endorepellin fragment consists of the amino acid sequence SEQ ID NO:10 residues 4182 to 4391 (SEQ ID NO:10) of perlecan.